Barclays’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.07M | Sell |
26,808
-68,504
| -72% | -$12M | ﹤0.01% | 1809 |
|
|
2025
Q4 | $16.2M | Buy |
95,312
+29,733
| +45% | +$4.56M | ﹤0.01% | 1365 |
|
|
2025
Q3 | $8.64M | Buy |
65,579
+13,568
| +26% | +$1.63M | ﹤0.01% | 1781 |
|
|
2025
Q2 | $5.52M | Sell |
52,011
-7,776
| -13% | -$845K | ﹤0.01% | 2040 |
|
|
2025
Q1 | $7.42M | Sell |
59,787
-6,941
| -10% | -$905K | ﹤0.01% | 1616 |
|
|
2024
Q4 | $8.22M | Buy |
66,728
+27,518
| +70% | +$3.24M | ﹤0.01% | 1722 |
|
|
2024
Q3 | $4.37M | Buy |
39,210
+6,289
| +19% | +$689K | ﹤0.01% | 2204 |
|
|
2024
Q2 | $3.51M | Sell |
32,921
-65,135
| -66% | -$7.16M | ﹤0.01% | 1751 |
|
|
2024
Q1 | $11.8M | Sell |
98,056
-10,285
| -9% | -$1.26M | ﹤0.01% | 1276 |
|
|
2023
Q4 | $13.3M | Buy |
108,341
+8,975
| +9% | +$1.12M | ﹤0.01% | 1309 |
|
|
2023
Q3 | $12.9M | Buy |
99,366
+8,834
| +10% | +$1.18M | 0.01% | 892 |
|
|
2023
Q2 | $11.2M | Buy |
90,532
+23,851
| +36% | +$3.21M | 0.01% | 948 |
|
|
2023
Q1 | $9.76M | Sell |
66,681
-6,268
| -9% | -$927K | ﹤0.01% | 1174 |
|
|
2022
Q4 | $11.6M | Buy |
72,949
+29,462
| +68% | +$4.32M | 0.01% | 1138 |
|
|
2022
Q3 | $5.8M | Buy |
43,487
+2,378
| +6% | +$362K | 0.01% | 1076 |
|
|
2022
Q2 | $6.41M | Buy |
41,109
+4,623
| +13% | +$712K | ﹤0.01% | 1209 |
|
|
2022
Q1 | $5.68M | Sell |
36,486
-38,975
| -52% | -$5.66M | ﹤0.01% | 1178 |
|
|
2021
Q4 | $9.61M | Sell |
75,461
-21,472
| -22% | -$2.82M | ﹤0.01% | 1288 |
|
|
2021
Q3 | $12.6M | Buy |
96,933
+17,327
| +22% | +$2.62M | 0.01% | 1068 |
|
|
2021
Q2 | $14.1M | Buy |
79,606
+31,729
| +66% | +$5.5M | 0.01% | 1049 |
|
|
2021
Q1 | $7.87M | Buy |
47,877
+15,469
| +48% | +$2.55M | ﹤0.01% | 1194 |
|
|
2020
Q4 | $5.35M | Sell |
32,408
-3,291
| -9% | -$490K | ﹤0.01% | 1478 |
|
|
2020
Q3 | $5.09M | Sell |
35,699
-21,093
| -37% | -$2.61M | ﹤0.01% | 1382 |
|
|
2020
Q2 | $6.27M | Sell |
56,792
-9,825
| -15% | -$1.09M | ﹤0.01% | 1207 |
|
|
2020
Q1 | $6.64M | Sell |
66,617
-45,702
| -41% | -$5.91M | 0.01% | 1256 |
|
|
2019
Q4 | $16.8M | Buy |
112,319
+28,564
| +34% | +$3.89M | 0.01% | 1048 |
|
|
2019
Q3 | $10.7M | Buy |
83,755
+16,746
| +25% | +$2.24M | 0.01% | 1239 |
|
|
2019
Q2 | $9.55M | Buy |
67,009
+9,325
| +16% | +$1.25M | 0.01% | 1386 |
|
|
2019
Q1 | $8.24M | Sell |
57,684
-11,760
| -17% | -$1.53M | 0.01% | 1346 |
|
|
2018
Q4 | $8.61M | Buy |
69,444
+11,851
| +21% | +$1.76M | 0.01% | 1241 |
|
|
2018
Q3 | $9.69M | Buy |
57,593
+31,413
| +120% | +$5.4M | 0.01% | 1282 |
|
|
2018
Q2 | $4.51M | Buy |
26,180
+11,857
| +83% | +$1.94M | ﹤0.01% | 1806 |
|
|
2018
Q1 | $2.16M | Sell |
14,323
-23
| -0.2% | -$3.37K | ﹤0.01% | 2379 |
|
|
2017
Q4 | $1.93M | Sell |
14,346
-62,874
| -81% | -$8.72M | ﹤0.01% | 2458 |
|
|
2017
Q3 | $11.3M | Buy |
77,220
+12,876
| +20% | +$1.95M | 0.01% | 977 |
|
|
2017
Q2 | $10M | Sell |
64,344
-54,054
| -46% | -$8.27M | 0.01% | 970 |
|
|
2017
Q1 | $17.2M | Sell |
118,398
-62,168
| -34% | -$8.1M | 0.02% | 611 |
|
|
2016
Q4 | $19.7M | Buy |
180,566
+97,792
| +118% | +$10.9M | 0.02% | 604 |
|
|
2016
Q3 | $10.1M | Buy |
82,774
+3,954
| +5% | +$533K | 0.01% | 874 |
|
|
2016
Q2 | $11.1M | Buy |
78,820
+13,913
| +21% | +$2.05M | 0.01% | 784 |
|
|
2016
Q1 | $8.44M | Buy |
64,907
+11,184
| +21% | +$1.39M | 0.01% | 850 |
|
|
2015
Q4 | $7.52M | Sell |
53,723
-17,293
| -24% | -$2.4M | 0.01% | 1045 |
|
|
2015
Q3 | $9.37M | Buy |
71,016
+53,246
| +300% | +$9.17M | 0.01% | 969 |
|
|
2015
Q2 | $3.13M | Buy |
17,770
+7,333
| +70% | +$1.32M | ﹤0.01% | 1866 |
|
|
2015
Q1 | $1.8M | Sell |
10,437
-371
| -3% | -$63.7K | ﹤0.01% | 2420 |
|
|
2014
Q4 | $1.76M | Sell |
10,808
-90,849
| -89% | -$15.1M | ﹤0.01% | 2644 |
|
|
2014
Q3 | $16.3M | Buy |
101,657
+64,847
| +176% | +$9.97M | 0.02% | 852 |
|
|
2014
Q2 | $5.41M | Buy |
36,810
+29,847
| +429% | +$4.14M | 0.01% | 1673 |
|
|
2014
Q1 | $960K | Buy |
6,963
+2,055
| +42% | +$309K | ﹤0.01% | 3278 |
|
|
2013
Q4 | $618K | Buy |
+4,908
| New | +$508K | ﹤0.01% | 3884 |
|
|
2013
Q3 | – | Sell |
-42,194
| Closed | -$2.9M | – | 7511 |
|
|
2013
Q2 | $2.9M | Buy |
+42,194
| New | +$2.58M | ﹤0.01% | 2126 |
|
Other funds holding JAZZ
VPM
VCM
EC
Barclays's JAZZ Position: Q1 2026 in Review
Barclays reduced its Jazz Pharmaceuticals (JAZZ) stake by 72% in Q1 2026, selling an estimated $12M and leaving 26,808 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1809.
Barclays first reported a position in JAZZ in Q2 2013 and has held it in 51 quarters since. The position peaked at $19.7M in Q4 2016. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Barclays held 26,808 shares of Jazz Pharmaceuticals worth $5.07M as of Q1 2026.
- Barclays sold 68,504 Jazz Pharmaceuticals shares in Q1 2026, an estimated $12M.
- Jazz Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1809 holding.
- Barclays first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Barclays's Jazz Pharmaceuticals position peaked at $19.7M in Q4 2016.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.